

10/568466

| | | |
|--|---|---|
| FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Atty. Docket No. X-16410 | International Serial No. PCT/US2004/025593 |
| | First Applicant ALLEN, Albert John | |
| | Filing Date US Nat'l Entry (if applicable) | Group |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| | AA | US 5 281 624 A | 01-25-1994 | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---|--------------------------------|---|---|----------------|
| | | Country Code ³ -Number ⁴ - Kind Code ⁵ (if known) | | | | |
| /RC/ | BA | WO 02/070457 | 09-12-2002 | | | |
| /RC/ | BB | EP 0 721 777 A | 07-17-1996 | | | |
| /RC/ | BC | WO 01/62236 A | 08-30-2001 | | | |
| /RC/ | BD | WO 02/053140 A | 07-11-2002 | | | |
| /RC/ | BE | WO 01/01973 A | 01-11-2001 | | | |
| /RC/ | BF | WO 02/102297 A | 12-27-2002 | | | |
| | BG | | | | | |
| | BH | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published. | T ⁶ |
|-----------------------|--------------------------|--|----------------|
| /RC/ | CA | International Preliminary Report on Patentability | |
| /RC/ | CB | International Search Report | |
| /RC/ | CC | GRAUL A I, "Annual Update 2003: Drugs for Psychiatric Disorders and Substance Abuse" <i>Drugs of the Future</i> (2003) Vol. 28, No. 11, pgs. 1103-1144 | |
| /RC/ | CD | TAYLOR E., et al., "European clinical guidelines for hyperkinetic disorder - first upgrade", <i>European Child and Adolescent Psychiatry</i> , (2004) Vol. 13, Suppl. 1, pgs. 1/7-1/30 | |
| /RC/ | CE | ANONYMOUS, "Medication Reference", <i>Internet Article -Autism Center</i> , August 2003 | |
| /RC/ | CF | GORDON C T, et al., <i>American Journal of Psychiatry</i> , (1992) Vol. 149, No. 3, pgs. 363-366 | |

| | | | |
|--|---------------|--|--|
| FORM PTO 1449 (modified) | | Atty. Docket No. X-16410 | International Serial No. PCT/US2004/025593 466 |
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | First Applicant ALLEN, Albert John | |
| | | Filing Date US Nat'l Entry (if applicable) | Group |
| NON PATENT LITERATURE DOCUMENTS | | | |
| Examiner Initials* | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published. | |

| | | | |
|------|----|---|--|
| /RC/ | CG | GEHLERT D R., et al., "(R)-Thionisoxetine, A Potent and Selective Inhibitor of Central and Peripheral Norepinephrine Uptake", <i>Life Sciences</i> , (1995) Vol. 56, No. 22, pgs 1915-1920 | |
| /RC/ | CH | GEHLERT D R., "Localization of rat brain binding sites for tritiated tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites" <i>Neuroscience Letters</i> , (1993) Vol. 157, No. 2, pages 203-206 | |
| /RC/ | CI | DSM-IV, Fourth Edition, "Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence", pgs. 37-39; 65-78 | |
| /RC/ | CJ | DSM-IV-TR, Fourth Edition, "Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence", pgs. 39-41; 69-84 | |
| /RC/ | CK | DSM-III-R, Third Edition, "Disorders Usually First Evident in Infancy, Childhood, or Adolescence", pgs. 27-28; 33-49 | |
| /RC/ | CL | Medication Reference Tables, "The latest data on medications for PDD symptoms", (2005) pgs. 1-5 | |
| /RC/ | CM | WONG D T, et al., "A New Inhibitor of Norepinephrine Uptake Devoid of Affinity for Receptors in Rat Brain" <i>The Journal of Pharmacology and Experimental Therapeutics</i> , (1982) Vol. 222, No. 1, pgs. 61-65 | |
| /RC/ | CN | Cusak B, et al., "Binding of antidepressants to human brain receptors: focus on newer generation compounds" <i>Psychopharmacology</i> , (1994) Vol. 114, pgs. 559-565 | |
| /RC/ | CO | Results of an Atomoxetine Pilot Study in Children with Autism Spectrum Disorders, pgs. 1-14 | |
| | CP | | |

| | | | |
|-----------------------|-----------------|-----------------|------------|
| Examiner Signature | /Renee Claytor/ | Date Considered | 07/20/2007 |
|-----------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.